European Commission approves Eliquis for Deep Vein Thrombosis and Pulmonary Embolism - BMS + Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announced that the European Commission has approved Eliquis (apixaban) for the treatment of Deep Vein Thrombosis and Pulmonary Embolism (DVT & PE), and the prevention of recurrent DVT and PE in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway. Eliquis is also approved in the EU for the prevention of venous thromboembolism (VTE) in adults who have undergone elective total hip or knee replacement surgery, and for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factor.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins